Third Harmonic Bio Cuts Workforce in Half Amid Broader Evaluation of THB335

Dow Jones

02-11

By Denny Jacob

Third Harmonic Bio is cutting its workforce in half as part of a broader evaluation of THB335.

The pharmaceutical products developer said it is initiating a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value through a strategic transaction and/or business combination.

"As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company," said Chief Executive Natalie Holles.

The San Francisco company had 30 employees as of Dec. 31, 2023, according to a securities filing.

Third Harmonic also said it is halting all non-THB335 related research and discovery activities.

The company's announcements came as it disclosed data from a Phase 1 clinical trial of THB335.

Third Harmonic said THB335 was generally safe and well tolerated in the SAD cohorts. It noted there were three subjects in the MAD cohorts with isolated, transient asymptomatic transaminase elevations, with two of the three subjects having received a placebo. The company said it doesn't believe the single transaminase event in the active subject is drug-related.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

February 11, 2025 07:50 ET (12:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2510858543"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510858543\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510858543?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510858543","market":"sg","top_or_hot":-1,"title":"Third Harmonic Bio Cuts Workforce in Half Amid Broader Evaluation of THB335","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Third Harmonic Bio is cutting its workforce in half as part of a broader evaluation of THB335. \n</p>\n<p>\n  The pharmaceutical products developer said it is initiating a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value through a strategic transaction and/or business combination. \n</p>\n<p>\n  \"As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company,\" said Chief Executive Natalie Holles. \n</p>\n<p>\n  The San Francisco company had 30 employees as of Dec. 31, 2023, according to a securities filing. \n</p>\n<p>\n  Third Harmonic also said it is halting all non-THB335 related research and discovery activities. \n</p>\n<p>\n  The company's announcements came as it disclosed data from a Phase 1 clinical trial of THB335. \n</p>\n<p>\n  Third Harmonic said THB335 was generally safe and well tolerated in the SAD cohorts. It noted there were three subjects in the MAD cohorts with isolated, transient asymptomatic transaminase elevations, with two of the three subjects having received a placebo. The company said it doesn't believe the single transaminase event in the active subject is drug-related. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 11, 2025 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Third Harmonic Bio Cuts Workforce in Half Amid Broader Evaluation of THB335</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThird Harmonic Bio Cuts Workforce in Half Amid Broader Evaluation of THB335\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-11 20:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Third Harmonic Bio is cutting its workforce in half as part of a broader evaluation of THB335. \n</p>\n<p>\n  The pharmaceutical products developer said it is initiating a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value through a strategic transaction and/or business combination. \n</p>\n<p>\n  \"As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company,\" said Chief Executive Natalie Holles. \n</p>\n<p>\n  The San Francisco company had 30 employees as of Dec. 31, 2023, according to a securities filing. \n</p>\n<p>\n  Third Harmonic also said it is halting all non-THB335 related research and discovery activities. \n</p>\n<p>\n  The company's announcements came as it disclosed data from a Phase 1 clinical trial of THB335. \n</p>\n<p>\n  Third Harmonic said THB335 was generally safe and well tolerated in the SAD cohorts. It noted there were three subjects in the MAD cohorts with isolated, transient asymptomatic transaminase elevations, with two of the three subjects having received a placebo. The company said it doesn't believe the single transaminase event in the active subject is drug-related. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 11, 2025 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2510858543","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510858543","pubTimestamp":1739278200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Third Harmonic Bio is cutting its workforce in half as part of a broader evaluation of THB335.The pharmaceutical products developer said it is initiating a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value through a strategic transaction and/or business combination.\"As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company,\" said Chief Executive Natalie Holles.The San Francisco company had 30 employees as of Dec. 31, 2023, according to a securities filing.Third Harmonic also said it is halting all non-THB335 related research and discovery activities.Third Harmonic said THB335 was generally safe and well tolerated in the SAD cohorts. It noted there were three subjects in the MAD cohorts with isolated, tra","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Third Harmonic Bio在THB335更广泛的评估中裁员一半","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLIT":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Third Harmonic Bio is cutting its workforce in half as part of a broader evaluation of THB335. \n\n\n  The pharmaceutical products developer said it is initiating a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value through a strategic transaction and/or business combination. \n\n\n  \"As we evaluate the competitive landscape and current market dynamics, we believe the right thing for our stakeholders is to evaluate a full range of strategic transactions and/or business combinations to maximize value creation across all assets in the company,\" said Chief Executive Natalie Holles. \n\n\n  The San Francisco company had 30 employees as of Dec. 31, 2023, according to a securities filing. \n\n\n  Third Harmonic also said it is halting all non-THB335 related research and discovery activities. \n\n\n  The company's announcements came as it disclosed data from a Phase 1 clinical trial of THB335. \n\n\n  Third Harmonic said THB335 was generally safe and well tolerated in the SAD cohorts. It noted there were three subjects in the MAD cohorts with isolated, transient asymptomatic transaminase elevations, with two of the three subjects having received a placebo. The company said it doesn't believe the single transaminase event in the active subject is drug-related. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2025 07:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}